The phase 1 clinical trial using botanical new drug BEL-X is targeting advanced refractory solid tumors patients to test BEL-X’s maximum tolerated dose and safety.

This trial received approval from US FDA (#127857) on 12/17/2015. It will be conducted at both the Clinical Trial Center of National Taiwan University Hospital and the Clinical Trial Center of National Cheng Kung University Hospital. The FDA-approved clinical trial protocol will bepart of the submission package submitted to TFDA as well as the IRB’s atthe two hospitals simultaneously. The trial is expected to formally commence in 2017Q1. 

The company will design phase 2 clinical trials based on the outcome from the above-mentioned phase 1 trial. Liver cancer, major cancer among Chinese people, lung cancer, the leading cause of cancer death globally, and colorectal cancer, with fast increasing prevalence in recent years, and other cancers without good treatment drugs will be target indications for phase 2 clinical trials. The botanical new drug BEL-X is expected to demonstrate better efficacy and benefit for the well-being of cancer patients.